-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
OncoSec Medical (NASDAQ:ONCS) Now Covered by Analysts at StockNews.com
OncoSec Medical (NASDAQ:ONCS) Now Covered by Analysts at StockNews.com
StockNews.com began coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research note released on Thursday. The firm issued a sell rating on the biotechnology company's stock.
Separately, BTIG Research cut OncoSec Medical from a buy rating to a neutral rating in a research report on Monday, November 14th.
Get OncoSec Medical alerts:OncoSec Medical Trading Down 1.7 %
Shares of OncoSec Medical stock opened at $1.71 on Thursday. The business's fifty day simple moving average is $7.71 and its 200 day simple moving average is $12.79. The firm has a market capitalization of $5.08 million, a P/E ratio of -0.08 and a beta of 1.48. OncoSec Medical has a 12 month low of $1.50 and a 12 month high of $31.90.
Institutional Investors Weigh In On OncoSec Medical
An institutional investor recently raised its position in OncoSec Medical stock. Renaissance Technologies LLC boosted its position in OncoSec Medical Incorporated (NASDAQ:ONCS – Get Rating) by 48.8% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 72,898 shares of the biotechnology company's stock after acquiring an additional 23,900 shares during the period. Renaissance Technologies LLC owned 0.19% of OncoSec Medical worth $54,000 as of its most recent SEC filing. 13.22% of the stock is owned by institutional investors.OncoSec Medical Company Profile
(Get Rating)
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.
Recommended Stories
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- Is AMC Entertainment Stock Worth Taking Down Here?
- Is it Time to Take a Bite into Domino's Pizza?
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com began coverage on shares of OncoSec Medical (NASDAQ:ONCS – Get Rating) in a research note released on Thursday. The firm issued a sell rating on the biotechnology company's stock.
證券新聞網開始對股票的報導 腫瘤證券交易委員會 (NASDAQ: ONCS — 獲得評級) 在星期四發布的一份研究報告中。該公司對生物技術公司的股票發出了銷售評級。
Separately, BTIG Research cut OncoSec Medical from a buy rating to a neutral rating in a research report on Monday, November 14th.
另外，BTIG 研究將 OncoSec 醫療從購買評級降至中性評級，在 11 月 14 日星期一的研究報告中。
OncoSec Medical Trading Down 1.7 %
腫瘤證券交易指數下跌 1.7%
Shares of OncoSec Medical stock opened at $1.71 on Thursday. The business's fifty day simple moving average is $7.71 and its 200 day simple moving average is $12.79. The firm has a market capitalization of $5.08 million, a P/E ratio of -0.08 and a beta of 1.48. OncoSec Medical has a 12 month low of $1.50 and a 12 month high of $31.90.
康科醫療股份於星期四開盤 1.71 美元。該企業的五十天簡單移動平均線為 7.71 美元，其 200 天簡單移動平均線為 12.79 美元。該公司的市值為 508 萬美元，市盈率為 -0.08，測試值為 1.48。康科醫療有一個 12 個月的低點 1.50 美元和 12 個月的最高點 31.90 美元。
Institutional Investors Weigh In On OncoSec Medical
機構投資者權衡在 OncoSEC 醫療
OncoSec Medical Company Profile
醫療公司簡介
(Get Rating)
(取得評分)
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.
OncoSec Medical Incorporated 是一家後期免疫腫瘤醫學公司，致力於設計、開發和商業化以 DNA 為基礎的治療藥物，以刺激和增強抗腫瘤免疫反應，用於治療癌症。公司的產品線包括 KEYNOTE-695，目前正處於晚期黑色素瘤治療的二期試驗；TAVO +SARS-CoV-2 穗糖蛋白，正處於治療 COVID-19 的一期臨床試驗；TAVO + 依帕多斯塔 + 彭布羅利珠單抗治療鱗狀細胞癌和頸癌的第一期臨床試驗中。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- Is AMC Entertainment Stock Worth Taking Down Here?
- Is it Time to Take a Bite into Domino's Pizza?
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- 免費索取有關癌症醫療研究報告
- AMC 娛樂股票值得在這裡下跌嗎？
- 是時候咬一口多米諾骨牌的披薩了嗎？
- 市場節拍：評論中的一周
- 哪兩家藍芯科技公司提出了他們的指導？
- 您應該擔心埃隆·馬斯克出售他的特斯拉股票嗎？
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.
接收有關 OncoSEC 醫療日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 OncoSec 醫療和相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧